Next Article in Journal
Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine
Next Article in Special Issue
Development and Optimization of an Enzyme Immunoassay to Detect Serum Antibodies against the Hepatitis E Virus in Pigs, Using Plant-Derived ORF2 Recombinant Protein
Previous Article in Journal
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants
Previous Article in Special Issue
Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer?
Review

Producing Vaccines against Enveloped Viruses in Plants: Making the Impossible, Difficult

Department of Biochemistry and Metabolism, John Innes Centre, Norwich NR4 7UH, UK
*
Author to whom correspondence should be addressed.
Current address: Piramal Healthcare UK Ltd., Piramal Pharma Solutions, Northumberland NE61 3YA, UK.
Academic Editor: Marcello Iriti
Received: 7 June 2021 / Revised: 7 July 2021 / Accepted: 8 July 2021 / Published: 13 July 2021
(This article belongs to the Special Issue Plant Based Vaccines—A Powerhouse for Global Health 2.0)
The past 30 years have seen the growth of plant molecular farming as an approach to the production of recombinant proteins for pharmaceutical and biotechnological uses. Much of this effort has focused on producing vaccine candidates against viral diseases, including those caused by enveloped viruses. These represent a particular challenge given the difficulties associated with expressing and purifying membrane-bound proteins and achieving correct assembly. Despite this, there have been notable successes both from a biochemical and a clinical perspective, with a number of clinical trials showing great promise. This review will explore the history and current status of plant-produced vaccine candidates against enveloped viruses to date, with a particular focus on virus-like particles (VLPs), which mimic authentic virus structures but do not contain infectious genetic material. View Full-Text
Keywords: alphavirus; Bunyavirales; coronavirus; Flaviviridae; hepatitis B virus; human immunodeficiency virus; Influenza virus; newcastle disease virus; plant molecular farming; plant-produced vaccines; rhabdovirus; virus-like particles alphavirus; Bunyavirales; coronavirus; Flaviviridae; hepatitis B virus; human immunodeficiency virus; Influenza virus; newcastle disease virus; plant molecular farming; plant-produced vaccines; rhabdovirus; virus-like particles
Show Figures

Figure 1

MDPI and ACS Style

Peyret, H.; Steele, J.F.C.; Jung, J.-W.; Thuenemann, E.C.; Meshcheriakova, Y.; Lomonossoff, G.P. Producing Vaccines against Enveloped Viruses in Plants: Making the Impossible, Difficult. Vaccines 2021, 9, 780. https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9070780

AMA Style

Peyret H, Steele JFC, Jung J-W, Thuenemann EC, Meshcheriakova Y, Lomonossoff GP. Producing Vaccines against Enveloped Viruses in Plants: Making the Impossible, Difficult. Vaccines. 2021; 9(7):780. https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9070780

Chicago/Turabian Style

Peyret, Hadrien, John F.C. Steele, Jae-Wan Jung, Eva C. Thuenemann, Yulia Meshcheriakova, and George P. Lomonossoff 2021. "Producing Vaccines against Enveloped Viruses in Plants: Making the Impossible, Difficult" Vaccines 9, no. 7: 780. https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9070780

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop